亮丙瑞林注射液联合米非司酮治疗子宫肌瘤的效果观察  

Therapetutic effect of leuprorelin injection combined with mifepristone on uterine myoma

作　　者：陈卓 李小华[1] 杨柳 Chen Zhuo;Li Xiaohua;Yang Liu(Department of Gynecology,Nanyang Second General Hospital,Nanyang 473000,China)

机构地区：[1]南阳市第二人民医院妇科,南阳473000

出　　处：《中国实用医刊》2023年第18期104-107,共4页Chinese Journal of Practical Medicine

摘　　要：目的分析亮丙瑞林注射液联合米非司酮治疗子宫肌瘤的效果。方法抽取2020年9月至2022年9月南阳市第二人民医院收治的子宫肌瘤患者84例,按随机数字表法分为对照组与观察组,每组42例。对照组应用亮丙瑞林注射液治疗,观察组在对照组基础上应用米非司酮治疗。比较两组治疗效果、肌瘤体积、子宫体积、性激素[黄体生成素(LH)、雌二醇(E2)]水平、胰岛素样生长因子1(IGF-1)水平、血管内皮生长因子(VEGF)水平及不良反应发生率。结果观察组总有效率(92.86%,39/42)高于对照组(73.81%,31/42),P<0.05。治疗后,观察组肌瘤体积、子宫体积小于对照组(P<0.05)。治疗后,观察组LH、E2水平低于对照组(P<0.05)。治疗后,观察组IGF-1、VEGF水平低于对照组(P<0.05)。观察组不良反应发生率(11.90%,5/42)与对照组(7.14%,3/42)比较差异未见统计学意义(P>0.05)。结论亮丙瑞林注射液联合米非司酮治疗子宫肌瘤,可调节性激素和IGF-1、VEGF表达,能缩小肌瘤和子宫体积,临床效果和安全性确切。Objective To analyze the effect of leuprorelin injection combined with mifepristone in the treatment of uterine myoma.Methods A total of 84 patients with uterine myoma treated in Nanyang Second General Hospital from September 2020 to September 2022 were selected,and they were divided into control group and observation group according to random number table method,with 42 cases in each group.The control group received leuprorelin injection,and the observation group received mifepristone based on the treatment of the control group.The curative effect,myoma volume,uterus volume,levels of sex hormones,including luteinizing hormone(LH)and estradiol(E2),insulin-like growth factor 1(IGF-1),vascular endothelial growth factor(VEGF)and incidence of adverse reaction were compared between the two groups.Results The total effective rate of the observation group(92.86%,39/42)was higher than that of the control group(73.81%,31/42),P<0.05.After treatment,the volume of myoma and uterus in the observation group were smaller than those in the control group(P<0.05).After treatment,the levels of LH and E2 in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of IGF-1 and VEGF in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group(11.90%,5/42)and the control group(7.14%,3/42),P>0.05.Conclusions Leuprorelin injection combined with mifepristone in the treatment of uterine myoma can regulate the expression of sex hormones,IGF-1 and VEGF,and reduce the volume of myoma and uterus,showing definite clinical effect and safety.

关 键 词：子宫肌瘤 亮丙瑞林 米非司酮 

分 类 号：R737.33[医药卫生—肿瘤]